about
Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factorDeterminants of the effectiveness of glucagon-like peptide-1 in type 2 diabetesEffect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trialComparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.Altered PI3-kinase/Akt signalling in skeletal muscle of young men with low birth weight.An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Studies of the association of Arg72Pro of tumor suppressor protein p53 with type 2 diabetes in a combined analysis of 55,521 Europeans.Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension.Effects of everyday life events on glucose, insulin, and glucagon dynamics in continuous subcutaneous insulin infusion-treated type 1 diabetes: collection of clinical data for glucose modeling.Hypomagnesemia, a risk factor in diabetic retinopathy.Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight.Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity.Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis.Proteomics reveals the effects of sustained weight loss on the human plasma proteomeInsulin analogues: have they changed insulin treatment and improved glycaemic control?The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes.Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.Smoking reduces insulin absorption from subcutaneous tissue.Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetesUnprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report.Pleiotropic effects of GIP on islet function involve osteopontin.Whole body clearance of norepinephrine. The significance of arterial sampling and of surgical stressEfficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell functionLiraglutide for treating type 1 diabetes.Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiotaPrenatal exposure to persistent organochlorine pollutants is associated with high insulin levels in 5-year-old girls.Gastric bypass surgery reveals independency of obesity and diabetes melitus type 2.Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis.Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.Link between GIP and osteopontin in adipose tissue and insulin resistanceExaggerated glucagon-like peptide 1 response is important for improved β-cell function and glucose tolerance after Roux-en-Y gastric bypass in patients with type 2 diabetes.Glucagon-like peptide-1, glucose homeostasis and diabetes.Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover studyGLP-1: physiological effects and potential therapeutic applications.
P50
Q26745621-8346613E-8C88-4FBA-8FDB-28DBB811BB9DQ28212600-29BFD485-119C-4D6F-A239-D64CD7807FA1Q28298603-D1199189-82B2-4155-87AD-0B2B9A396151Q32050034-718A9B61-A9C3-4F3D-B972-B89D251767C3Q33384632-FA3C5C8A-6C43-422E-96D7-D8B92088A1E7Q33786150-3F254F11-8437-45DB-89E2-5172AB67E402Q33809241-57E6472D-A165-430F-BBC3-59ECD4A4D9DAQ33898988-B55884A1-8C1E-49E3-ABF1-69BF875943D9Q34056541-87A1CEE0-E315-4D74-A7F9-9A606466734EQ34057134-21C09F76-4F2A-4B82-B4D9-F52AAD3C67D4Q34120734-A122D26A-284E-4273-9ECB-0495766B1E0DQ34180164-A7D72B86-1A1B-4F44-8847-339E105B9C1CQ34487164-50CAD99A-0FBE-4486-AE84-083BD3522209Q34494670-CD93D57E-3AE0-4BB7-91DA-A82A272B234FQ34547857-6B536F18-8F60-4A34-894E-671D7F2F323EQ34580951-847F92B5-780E-4077-8BE5-4DAF29F07018Q34655393-B8F6450F-7D80-486B-B13D-48EC4D2FBAFDQ34665186-8C88C0D6-68CF-4801-9435-9AEFF24491DBQ34747155-1C53458E-709C-4B03-97D5-ECE5632A1379Q35060123-38DE0775-6E0F-444A-A6E8-9451CA4CE053Q35165204-659DD288-3864-40FB-887B-1FCA0DCF840CQ35178140-D594C7A0-4BF2-487B-9784-0369DB33DEADQ35180057-DC4EFA15-DE7D-4B0A-AB62-3C8B5246826EQ35203933-92EA2F62-8666-4CEB-A002-AEA2CCFF62ABQ35331836-3AA26D15-AA4D-4CAA-9BE0-CE7C516F2FBFQ35652968-C09C7AF1-F4C4-4BBD-98A7-1A7ED860935CQ35797043-67FAF5B4-9759-428B-8DFF-253453E8C7EAQ35939660-6110586E-D73A-4E9C-8CA8-F56B76EBAD32Q36053361-B765404C-62FC-414A-988F-3F44988567EBQ36172563-DC498DBD-7590-412E-907B-19E3889CD916Q36187926-1A40E39A-DC59-451F-B14A-8BD85EF3DA88Q36509439-5A83C993-1AD4-4A80-B914-38A508FDFA4BQ36633074-2C4CF20B-D39D-4B56-BA42-4314683FD314Q36633079-A3EE8094-7DEF-4899-8F1B-BBDDBC22953EQ36783856-428E8E43-5FBE-45F3-A0B8-39C8AA5BE391Q36867588-D7C6C179-101D-4E37-8C8E-7A4BE385A041Q37110621-AE233F32-65A9-4A00-894A-4B847FD586E3Q37114343-91F2F4FB-A047-4F37-BBFB-8746559C3B4FQ37125983-8EF75CC3-953A-44BA-8665-0BF9F1045F37Q37147221-9CC59B11-E8EC-48D7-B7CE-8B295FF1F6AF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Sten Madsbad
@ast
Sten Madsbad
@en
Sten Madsbad
@es
Sten Madsbad
@nl
Sten Madsbad
@sl
type
label
Sten Madsbad
@ast
Sten Madsbad
@en
Sten Madsbad
@es
Sten Madsbad
@nl
Sten Madsbad
@sl
altLabel
Madsbad S
@en
prefLabel
Sten Madsbad
@ast
Sten Madsbad
@en
Sten Madsbad
@es
Sten Madsbad
@nl
Sten Madsbad
@sl
P214
P106
P21
P214
P31
P496
0000-0002-5017-1815
P7859
viaf-187830107